Please use this identifier to cite or link to this item:
Title: 3D-QSAR Studies, Molecular Docking, Molecular Dynamic Simulation, and ADMET Proprieties of Novel Pteridinone Derivatives as PLK1 Inhibitors for the Treatment of Prostate Cancer
Authors: Er-rajy, Mohammed$Other$Other
El fadili, Mohamed $Other$Other
Imtara, Hamada $AAUP$Palestinian
Saeed, Aamir $Other$Other
Ur Rehman, Abid $Other$Other
Zarougui, Sara $Other$Other
A. Abdullah, Shaef $Other$Other
Alahdab, Ahmad$Other$Other
Khalid Parvez, Mohammad $Other$Other
Elhallaoui, Menana $Other$Other
Issue Date: 26-Dec-2022
Publisher: Life
Abstract: Overexpression of polo-like kinase 1 (PLK1) has been found in many different types of cancers. With its essential role in cell proliferation, PLK1 has been determined to be a broad-spectrum anti-cancer target. In this study, 3D-QSAR, molecular docking, and molecular dynamics (MD) simulations were applied on a series of novel pteridinone derivatives as PLK1 inhibitors to discover anti-cancer drug candidates. In this work, three models—CoMFA (Q2 = 0.67, R2 = 0.992), CoMSIA/SHE (Q2 = 0.69, R2 = 0.974), and CoMSIA/SEAH (Q2 = 0.66, R2 = 0.975)—of pteridinone derivatives were established. The three models that were established gave R2 pred = 0.683, R2 pred = 0.758, and R2 pred = 0.767, respectively. Thus, the predictive abilities of the three proposed models were successfully evaluated. The relations between the different champs and activities were well-demonstrated by the contour chart of the CoMFA and CoMSIA/SEAH models. The results of molecular docking indicated that residues R136, R57, Y133, L69, L82, and Y139 were the active sites of the PLK1 protein (PDB code: 2RKU), in which the more active ligands can inhibit the enzyme of PLK1. The results of the molecular dynamic MD simulation diagram were obtained to reinforce the previous molecular docking results, which showed that both inhibitors remained stable in the active sites of the PLK1 protein (PDB code: 2RKU) for 50 ns. Finally, a check of the ADME-Tox properties of the two most active molecules showed that molecular N◦ 28 could represent a good drug candidate for the therapy of prostate cancer diseases.
Appears in Collections:Faculty & Staff Scientific Research publications

Files in This Item:
File Description SizeFormat 
Article 3.pdf12.2 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Admin Tools